Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project

Elisabeth Frank, Dieter Maier, Juha Pajula, Tommi Suvitaival, Faith Borgan, Markus Butz-Ostendorf, Alexander Fischer, Jarmo Hietala, Oliver Howes, Tuulia Hyötyläinen, Joost Janssen, Heikki Laurikainen, Carmen Moreno, Jaana Suvisaari, Mark van Gils, Matej Orešič (Corresponding Author)

Research output: Contribution to journalReview ArticleScientificpeer-review

6 Citations (Scopus)

Abstract

Psychotic disorders are associated with metabolic abnormalities including alterations in glucose and lipid metabolism. A major challenge in the treatment of psychosis is to identify patients with vulnerable metabolic profiles who may be at risk of developing cardiometabolic co-morbidities. It is established that both central and peripheral metabolic organs use lipids to control energy balance and regulate peripheral insulin sensitivity. The endocannabinoid system, implicated in the regulation of glucose and lipid metabolism, has been shown to be dysregulated in psychosis. It is currently unclear how these endocannabinoid abnormalities relate to metabolic changes in psychosis. Here we review recent research in the field of metabolic co-morbidities in psychotic disorders as well as the methods to study them and potential links to the endocannabinoid system. We also describe the bioinformatics platforms developed in the EU project METSY for the investigations of the biological etiology in patients at risk of psychosis and in first episode psychosis patients. The METSY project was established with the aim to identify and evaluate multi-modal peripheral and neuroimaging markers that may be able to predict the onset and prognosis of psychiatric and metabolic symptoms in patients at risk of developing psychosis and first episode psychosis patients. Given the intrinsic complexity and widespread role of lipid metabolism, a systems biology approach which combines molecular, structural and functional neuroimaging methods with detailed metabolic characterisation and multi-variate network analysis is essential in order to identify how lipid dysregulation may contribute to psychotic disorders. A decision support system, integrating clinical, neuropsychological and neuroimaging data, was also developed in order to aid clinical decision making in psychosis. Knowledge of common and specific mechanisms may aid the etiopathogenic understanding of psychotic and metabolic disorders, facilitate early disease detection, aid treatment selection and elucidate new targets for pharmacological treatments.

Original languageEnglish
Pages (from-to)40-46
Number of pages7
JournalEuropean Psychiatry
Volume50
DOIs
Publication statusPublished - 1 Apr 2018
MoE publication typeA2 Review article in a scientific journal

Fingerprint

Systems Analysis
Psychotic Disorders
Research
Endocannabinoids
Lipid Metabolism
Neuroimaging
Clinical Decision Support Systems
Morbidity
Lipids
Glucose
Functional Neuroimaging
Systems Biology
Metabolome
Computational Biology
Psychiatry
Insulin Resistance
Early Diagnosis
Therapeutics
Pharmacology

Keywords

  • Bioinformatics
  • Biomarkers
  • Decision support systems
  • Endocannabinoid system
  • Lipid metabolism
  • Metabolomics
  • Psychoses
  • Schizophrenia

Cite this

Frank, Elisabeth ; Maier, Dieter ; Pajula, Juha ; Suvitaival, Tommi ; Borgan, Faith ; Butz-Ostendorf, Markus ; Fischer, Alexander ; Hietala, Jarmo ; Howes, Oliver ; Hyötyläinen, Tuulia ; Janssen, Joost ; Laurikainen, Heikki ; Moreno, Carmen ; Suvisaari, Jaana ; van Gils, Mark ; Orešič, Matej. / Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project. In: European Psychiatry. 2018 ; Vol. 50. pp. 40-46.
@article{2e6c35c6907b41a98103b5d656454bf4,
title = "Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project",
abstract = "Psychotic disorders are associated with metabolic abnormalities including alterations in glucose and lipid metabolism. A major challenge in the treatment of psychosis is to identify patients with vulnerable metabolic profiles who may be at risk of developing cardiometabolic co-morbidities. It is established that both central and peripheral metabolic organs use lipids to control energy balance and regulate peripheral insulin sensitivity. The endocannabinoid system, implicated in the regulation of glucose and lipid metabolism, has been shown to be dysregulated in psychosis. It is currently unclear how these endocannabinoid abnormalities relate to metabolic changes in psychosis. Here we review recent research in the field of metabolic co-morbidities in psychotic disorders as well as the methods to study them and potential links to the endocannabinoid system. We also describe the bioinformatics platforms developed in the EU project METSY for the investigations of the biological etiology in patients at risk of psychosis and in first episode psychosis patients. The METSY project was established with the aim to identify and evaluate multi-modal peripheral and neuroimaging markers that may be able to predict the onset and prognosis of psychiatric and metabolic symptoms in patients at risk of developing psychosis and first episode psychosis patients. Given the intrinsic complexity and widespread role of lipid metabolism, a systems biology approach which combines molecular, structural and functional neuroimaging methods with detailed metabolic characterisation and multi-variate network analysis is essential in order to identify how lipid dysregulation may contribute to psychotic disorders. A decision support system, integrating clinical, neuropsychological and neuroimaging data, was also developed in order to aid clinical decision making in psychosis. Knowledge of common and specific mechanisms may aid the etiopathogenic understanding of psychotic and metabolic disorders, facilitate early disease detection, aid treatment selection and elucidate new targets for pharmacological treatments.",
keywords = "Bioinformatics, Biomarkers, Decision support systems, Endocannabinoid system, Lipid metabolism, Metabolomics, Psychoses, Schizophrenia",
author = "Elisabeth Frank and Dieter Maier and Juha Pajula and Tommi Suvitaival and Faith Borgan and Markus Butz-Ostendorf and Alexander Fischer and Jarmo Hietala and Oliver Howes and Tuulia Hy{\"o}tyl{\"a}inen and Joost Janssen and Heikki Laurikainen and Carmen Moreno and Jaana Suvisaari and {van Gils}, Mark and Matej Orešič",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.eurpsy.2017.12.001",
language = "English",
volume = "50",
pages = "40--46",
journal = "European Psychiatry",
issn = "0924-9338",
publisher = "Elsevier",

}

Frank, E, Maier, D, Pajula, J, Suvitaival, T, Borgan, F, Butz-Ostendorf, M, Fischer, A, Hietala, J, Howes, O, Hyötyläinen, T, Janssen, J, Laurikainen, H, Moreno, C, Suvisaari, J, van Gils, M & Orešič, M 2018, 'Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project', European Psychiatry, vol. 50, pp. 40-46. https://doi.org/10.1016/j.eurpsy.2017.12.001

Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project. / Frank, Elisabeth; Maier, Dieter; Pajula, Juha; Suvitaival, Tommi; Borgan, Faith; Butz-Ostendorf, Markus; Fischer, Alexander; Hietala, Jarmo; Howes, Oliver; Hyötyläinen, Tuulia; Janssen, Joost; Laurikainen, Heikki; Moreno, Carmen; Suvisaari, Jaana; van Gils, Mark; Orešič, Matej (Corresponding Author).

In: European Psychiatry, Vol. 50, 01.04.2018, p. 40-46.

Research output: Contribution to journalReview ArticleScientificpeer-review

TY - JOUR

T1 - Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project

AU - Frank, Elisabeth

AU - Maier, Dieter

AU - Pajula, Juha

AU - Suvitaival, Tommi

AU - Borgan, Faith

AU - Butz-Ostendorf, Markus

AU - Fischer, Alexander

AU - Hietala, Jarmo

AU - Howes, Oliver

AU - Hyötyläinen, Tuulia

AU - Janssen, Joost

AU - Laurikainen, Heikki

AU - Moreno, Carmen

AU - Suvisaari, Jaana

AU - van Gils, Mark

AU - Orešič, Matej

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Psychotic disorders are associated with metabolic abnormalities including alterations in glucose and lipid metabolism. A major challenge in the treatment of psychosis is to identify patients with vulnerable metabolic profiles who may be at risk of developing cardiometabolic co-morbidities. It is established that both central and peripheral metabolic organs use lipids to control energy balance and regulate peripheral insulin sensitivity. The endocannabinoid system, implicated in the regulation of glucose and lipid metabolism, has been shown to be dysregulated in psychosis. It is currently unclear how these endocannabinoid abnormalities relate to metabolic changes in psychosis. Here we review recent research in the field of metabolic co-morbidities in psychotic disorders as well as the methods to study them and potential links to the endocannabinoid system. We also describe the bioinformatics platforms developed in the EU project METSY for the investigations of the biological etiology in patients at risk of psychosis and in first episode psychosis patients. The METSY project was established with the aim to identify and evaluate multi-modal peripheral and neuroimaging markers that may be able to predict the onset and prognosis of psychiatric and metabolic symptoms in patients at risk of developing psychosis and first episode psychosis patients. Given the intrinsic complexity and widespread role of lipid metabolism, a systems biology approach which combines molecular, structural and functional neuroimaging methods with detailed metabolic characterisation and multi-variate network analysis is essential in order to identify how lipid dysregulation may contribute to psychotic disorders. A decision support system, integrating clinical, neuropsychological and neuroimaging data, was also developed in order to aid clinical decision making in psychosis. Knowledge of common and specific mechanisms may aid the etiopathogenic understanding of psychotic and metabolic disorders, facilitate early disease detection, aid treatment selection and elucidate new targets for pharmacological treatments.

AB - Psychotic disorders are associated with metabolic abnormalities including alterations in glucose and lipid metabolism. A major challenge in the treatment of psychosis is to identify patients with vulnerable metabolic profiles who may be at risk of developing cardiometabolic co-morbidities. It is established that both central and peripheral metabolic organs use lipids to control energy balance and regulate peripheral insulin sensitivity. The endocannabinoid system, implicated in the regulation of glucose and lipid metabolism, has been shown to be dysregulated in psychosis. It is currently unclear how these endocannabinoid abnormalities relate to metabolic changes in psychosis. Here we review recent research in the field of metabolic co-morbidities in psychotic disorders as well as the methods to study them and potential links to the endocannabinoid system. We also describe the bioinformatics platforms developed in the EU project METSY for the investigations of the biological etiology in patients at risk of psychosis and in first episode psychosis patients. The METSY project was established with the aim to identify and evaluate multi-modal peripheral and neuroimaging markers that may be able to predict the onset and prognosis of psychiatric and metabolic symptoms in patients at risk of developing psychosis and first episode psychosis patients. Given the intrinsic complexity and widespread role of lipid metabolism, a systems biology approach which combines molecular, structural and functional neuroimaging methods with detailed metabolic characterisation and multi-variate network analysis is essential in order to identify how lipid dysregulation may contribute to psychotic disorders. A decision support system, integrating clinical, neuropsychological and neuroimaging data, was also developed in order to aid clinical decision making in psychosis. Knowledge of common and specific mechanisms may aid the etiopathogenic understanding of psychotic and metabolic disorders, facilitate early disease detection, aid treatment selection and elucidate new targets for pharmacological treatments.

KW - Bioinformatics

KW - Biomarkers

KW - Decision support systems

KW - Endocannabinoid system

KW - Lipid metabolism

KW - Metabolomics

KW - Psychoses

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85040608354&partnerID=8YFLogxK

U2 - 10.1016/j.eurpsy.2017.12.001

DO - 10.1016/j.eurpsy.2017.12.001

M3 - Review Article

C2 - 29361398

AN - SCOPUS:85040608354

VL - 50

SP - 40

EP - 46

JO - European Psychiatry

JF - European Psychiatry

SN - 0924-9338

ER -